

Appl. No. 10/763,451  
Amdt. Dated January 24, 2005  
Reply to Office action of November 15, 2004

### Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

Claim 1 (Cancelled).

Claims 2-54 (Previously Cancelled).

Claim 55 (Previously Presented). A compound of the formula:



or a pharmaceutically acceptable salt of said compound, in which:

W is -O-,

R<sup>1</sup> is located at the 3-position and is selected from methyl, bromo, or chloro,

R<sup>2</sup> is located at the 5-position and is selected from methyl, bromo, or chloro,

R<sup>3</sup> is located at the 2' position and is represented by hydrogen,

R<sup>4</sup> is located at the 3' position and is represented by -C(R<sup>14</sup>)(R<sup>15</sup>)(R<sup>16</sup>),

R<sup>5</sup> is located at the 4' position and is represented by hydroxy or methoxy,

R<sup>6</sup> is located at the 5' position and is represented by hydrogen,

R<sup>7</sup> is hydrogen,

R<sup>8</sup> is hydrogen,

R<sup>14</sup> is hydrogen, or -(C<sub>1</sub>-C<sub>6</sub>) alkyl,

Appl. No. 10/763,451

Amdt. Dated January 24, 2005

Reply to Office action of November 15, 2004

$R^{15}$  is hydrogen or  $-(C_1-C_6)$  alkyl,

$R^{16}$  is  $-(C_0-C_6)$ alkyl-aryl,

aryl is (a) phenyl optionally substituted with one or more substituents independently selected from Group Z; (b) naphthyl optionally substituted with one, or more substituents independently selected from Group Z or (c) biphenyl optionally substituted with one or more substituents independently selected from Group Z, and;

Group Z, for each occurrence, is independently selected from the group consisting of (a) hydrogen, (b) halogen, (c) trifluoromethyl, (d) hydroxy, (e)  $-OCF_3$ , (f)  $-CN$ , (g)  $-NO_2$ , and (h)  $-(C_1-C_6)$ alkyl.

Claim 56 (Previously Presented). A compound according to claim 55 in which  $R^1$  and  $R^2$  are each methyl.

Claim 57 (Previously Presented) A compound according to claim 55 in which  $R^5$  is hydroxy.

Claim 58 (Currently Amended). A compound according to claim 55 in which  $R^{16}$  is  $(C_0-C_1)$ alkyl-aryl.

Claim ~~58-59~~ (Currently Amended) A compound according to claim 58 in which aryl is phenyl, optionally substituted with one or more substituents independently selected from Group Z.

Claim ~~59-60~~ (Currently Amended) A compound according to claim 55 selected from the group consisting of:

- i) 2-{3-chloro-4-[3-(4-fluoro-benzyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-2H [1,2,4]triazine-3,5-dione;
- ii) 2-{4-[3-(4-fluoro-benzyl)-4-methoxy-phenoxy]-3,5-dimethyl-phenyl}-2H-[1,2,4]triazine-3,5-dione;
- iii) 2-{4-[3-[(4-fluoro-phenyl)-hydroxy-methyl]-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-2H-[1,2,4]triazine-3,5-dione;
- iv) 2-{4-[3-(4-fluoro-benzyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-2H-[1,2,4]triazine-3,5-dione

Appl. No. 10/763,451  
Amdt. Dated January 24, 2005  
Reply to Office action of November 15, 2004

- v) 2-{3,5-dichloro-4-[3-(4-fluoro-benzyl)-4-hydroxy-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione, and;
- vi) 2-{3,5-dibromo-4-[3-(4-fluoro-benzyl)-4-hydroxy-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione

Claim ~~60-61~~ (Currently Amended). A pharmaceutical composition comprising an effective amount of a compound of claim ~~4-55~~ or a pharmaceutically acceptable salt of said compound, in admixture with a pharmaceutically acceptable carrier.

Claim ~~64-62~~ (Currently Amended). 2-{4-[3-(4-Fluoro-benzyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-2H-[1,2,4]triazine-3,5-dione, or a pharmaceutically acceptable salt of said compound.

Claim ~~62-63~~ (Currently Amended). A topical pharmaceutical composition comprising an effective amount of a compound of claim ~~64-62~~, in admixture with a pharmaceutically acceptable topical carrier.